#Flumazenil antidote series

Pharmaceutical formulation and synthesis 4.5. Name and chemical formula of antidote 4.3. Areas where there is insufficient information toДЈ.12.5. Other consequential or supportive therapy 3.12.4. Benzodiazepine overdose or intoxication 3.11. Clinical studies - clinical trials 3.10.1. Analysis of the toxic agent in biologicalДЈ.6. Quantification of the antidote in biologicalДЈ.5.3. Pharmaceutical formulation and synthesis 3.5. Name and chemical formula of antidote 3.3. Areas where there is insufficient informationДў.12.5. Other consequential or supportive therapy 2.12.4. Effects in therapeutic use of opioids 2.10.2. Clinical studies - clinical trials 2.10.1. Pharmaceutical formulation and synthesis 2.5. Unit, Directorate-General Information Technologies and Industries,ДЎ.

EUR 14797 EN of the Commission of the EuropeanД¬ommunities, Dissemination of Scientific and Technical Knowledge (c) World Health Organization, Geneva, 1993 and Might be made of the information contained in this report. Neither the Commission of the European Communities nor any personДЄcting on behalf of the Commission is responsible for the use which World Health Organization in preference to others of a similar Products does not imply that they are endorsed or recommended by the The mention of specific companies or of certain manufacturers' Organization and of the Commission of the European Communities Published by Cambridge University Press on behalf of the World Health World Health Organization, Geneva, SwitzerlandД¬ommission of the European Communities, Luxembourg International Programme on Chemical Safety, Ulleval University Hospital, Oslo, Norway Practical use to clinical toxicologists and all those involved in theДepartment of Health, London, United Kingdom

#Flumazenil antidote series

The series will thereforeД¬ollate a wealth of useful information which will be of immense This scientific assessment is complemented byДetailed clinical information on routes of administration,Д¬ontraindications, precautions and so on. Will greatly assist in the selection and administration of anДЄppropriate antidote. TheДЄim has been to provide an authoritative consensus statement which This series will therefore summarise and assess, on an antidote byДЄntidote basis, their clinical use, mode of action and efficacy. Rigorous way the efficacy and use of a wide range of antidotes. To identify and evaluate for the first time in a scientific and Undertaken a major programme to evaluate antidotes used clinically Of the European Communities (CEC) (ILO/UNEP/WHO) have jointly

International Programme on Chemical Safety (IPCS) and the Commission Guidance on the use of antidotes to treat poisoning. This important new series will provide definitive and authoritative Volume 2 Antidotes for poisoning by cyanide Volume 1 Naloxone, flumazenil and dantrolene as antidotes IPCS International Programme on Chemical SafetyД¬EC Commission of the European Communities Naloxone, Flumazenil and Dantrolene as Antidotes IPCS/CEC EVALUATION OF ANTIDOTES SERIES VOLUME 1 NALOXONE, FLUMAZENIL AND DANTROLENE AS ANTIDOTES